https://www.immunovant.com/ https://www.immunovant.com/about-us https://www.immunovant.com/about-us/our-leadership https://www.immunovant.com/our-science/introduction-to-fcrn https://www.immunovant.com/our-science/pipeline-and-therapeutic-areas https://www.immunovant.com/patients-caregivers/our-commitment https://www.immunovant.com/patients-caregivers/therapeutic-areas-clinical-trials https://www.immunovant.com/investors https://www.immunovant.com/investors/news-events https://www.immunovant.com/investors/news-events/press-releases https://www.immunovant.com/investors/news-events/ir-calendar https://www.immunovant.com/investors/news-events/presentations https://www.immunovant.com/investors/news-events/email-alerts https://www.immunovant.com/investors/company-information https://www.immunovant.com/investors/company-information/executive-leadership-team https://www.immunovant.com/investors/company-information/contacts https://www.immunovant.com/investors/company-information/faq https://www.immunovant.com/investors/financials https://www.immunovant.com/investors/financials/financial-results https://www.immunovant.com/investors/financials/income-statement https://www.immunovant.com/investors/financials/balance-sheet https://www.immunovant.com/investors/financials/cash-flow https://www.immunovant.com/investors/stock-data/quote https://www.immunovant.com/investors/stock-data/charts https://www.immunovant.com/investors/stock-data/historical-data https://www.immunovant.com/investors/stock-data/analyst-coverage https://www.immunovant.com/investors/sec-filings https://www.immunovant.com/investors/sec-filings/all-sec-filings https://www.immunovant.com/investors/corporate-governance https://www.immunovant.com/investors/corporate-governance/board-of-directors https://www.immunovant.com/investors/corporate-governance/board-committees https://www.immunovant.com/investors/corporate-governance/governance-documents https://www.immunovant.com/investors/corporate-governance/whistleblower-policy https://www.immunovant.com/join-us/values-culture https://www.immunovant.com/join-us/explore-careers https://www.immunovant.com/contact-us https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab https://www.immunovant.com/investors/news-events/press-releases/detail/80/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/79/immunovant-to-report-financial-results-for-the-third https://www.immunovant.com/investors/news-events/press-releases/detail/78/immunovant-announces-pricing-of-550-million-common-stock https://www.immunovant.com/investors/news-events/press-releases/detail/77/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/76/immunovant-to-report-financial-results-for-the-second https://www.immunovant.com/investors/news-events/press-releases/detail/75/immunovant-unveils-durability-and-treatment-free-six-month https://www.immunovant.com/investors/news-events/press-releases/detail/74/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant https://www.immunovant.com/investors/news-events/press-releases/detail/71/immunovant-announces-positive-results-for-batoclimab https://www.immunovant.com/investors/news-events/press-releases/detail/70/immunovant-to-host-investor-webcast-at-8-00-am-et-on https://www.immunovant.com/investors/news-events/press-releases/detail/69/immunovant-reports-financial-results-for-the-quarter-ended https://www.immunovant.com/investors/news-events/press-releases/detail/68/immunovant-announces-450-million-private-placement https://www.immunovant.com/investors/news-events/press-releases/detail/67/immunovant-provides-development-updates-and-reports https://www.immunovant.com/investors/news-events/press-releases/detail/66/immunovant-announces-oral-presentation-of-late-breaking https://www.immunovant.com/investors/news-events/press-releases/detail/65/immunovant-provides-update-on-graves-disease-development https://www.immunovant.com/investors/news-events/press-releases/detail/64/immunovant-to-host-graves-disease-program-update-on https://www.immunovant.com/investors/news-events/press-releases/detail/63/immunovant-reports-financial-results-and-provides-corporate https://www.immunovant.com/investors/news-events/press-releases/detail/62/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/61/immunovant-awarded-u-s-patent-for-imvt-1402 https://www.immunovant.com/investors/news-events/press-releases/detail/60/immunovant-reports-financial-results-and-provides-corporate https://www.immunovant.com/investors/news-events/press-releases/detail/59/immunovant-to-present-at-the-42nd-annual-j-p-morgan https://www.immunovant.com/investors/news-events/press-releases/detail/58/immunovant-reports-positive-initial-phase-2-results-for https://www.immunovant.com/investors/news-events/press-releases/detail/57/immunovant-announces-positive-imvt-1402-initial-600-mg-mad https://www.immunovant.com/investors/news-events/press-releases/detail/56/immunovant-to-present-at-upcoming-investor-conferences https://www.immunovant.com/investors/news-events/press-releases/detail/55/immunovant-reports-financial-results-and-provides-corporate https://www.immunovant.com/investors/news-events/press-releases/detail/54/immunovant-announces-closing-of-upsized-common-stock https://www.immunovant.com/investors/news-events/press-releases/detail/53/immunovant-announces-pricing-of-450-million-common-stock https://www.immunovant.com/investors/news-events/press-releases/detail/52/immunovant-announces-proposed-offering-of-300-million-of https://www.immunovant.com/investors/news-events/press-releases/detail/51/immunovant-announces-positive-initial-imvt-1402-phase-1-sad https://www.immunovant.com/investors/news-events/press-releases/detail/50/immunovant-to-host-conference-call-and-webcast-to-report https://www.immunovant.com/investors/news-events/press-releases/detail/49/immunovant-reports-financial-results-and-provides-corporate https://www.immunovant.com/investors/news-events/press-releases/detail/48/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/47/immunovant-reports-financial-results-and-recent-business https://www.immunovant.com/investors/news-events/press-releases/detail/46/immunovant-to-present-at-guggenheim-4th-annual-immunology https://www.immunovant.com/investors/news-events/press-releases/detail/45/immunovant-reports-financial-results-and-recent-business https://www.immunovant.com/investors/news-events/press-releases/detail/44/immunovant-announces-pricing-of-75-0-million-underwritten https://www.immunovant.com/investors/news-events/press-releases/detail/43/immunovant-announces-imvt-1402-a-next-generation-anti-fcrn https://www.immunovant.com/investors/news-events/press-releases/detail/42/immunovant-to-present-at-roivant-investor-day-on-september https://www.immunovant.com/investors/news-events/press-releases/detail/41/immunovant-to-present-at-the-h-c-wainwright-24th-annual https://www.immunovant.com/investors/news-events/press-releases/detail/40/immunovant-announces-two-new-development-programs-for https://www.immunovant.com/investors/news-events/press-releases/detail/38/immunovant-to-host-investor-webcast-to-announce-two-new https://www.immunovant.com/investors/news-events/press-releases/detail/37/immunovant-reports-financial-results-and-recent-business https://www.immunovant.com/investors/news-events/press-releases/detail/36/immunovant-achieves-alignment-with-fda-on-plans-for-phase-3 https://www.immunovant.com/investors/news-events/press-releases/detail/35/immunovant-to-report-fourth-quarter-and-full-year-2022 https://www.immunovant.com/investors/news-events/press-releases/detail/34/immunovant-to-present-at-the-h-c-wainwright-global https://www.immunovant.com/investors/news-events/press-releases/detail/33/immunovant-to-present-at-the-ubs-global-healthcare https://www.immunovant.com/investors/news-events/press-releases/detail/32/immunovant-to-present-at-lifesci-partners-immunology-and https://www.immunovant.com/investors/news-events/press-releases/detail/31/immunovant-to-host-virtual-rd-day-on-march-30-2022 https://www.immunovant.com/investors/news-events/press-releases/detail/30/immunovant-to-present-at-the-11th-annual-svb-leerink-global https://www.immunovant.com/investors/news-events/press-releases/detail/29/immunovant-reports-financial-results-for-the-quarter-ended https://www.immunovant.com/investors/news-events/press-releases/detail/28/immunovant-appoints-mark-levine-as-chief-legal-officer https://www.immunovant.com/investors/news-events/press-releases/detail/27/immunovant-to-present-at-the-40th-annual-j-p-morgan https://www.immunovant.com/investors/news-events/press-releases/detail/26/immunovant-provides-regulatory-update-regarding-initiation https://www.immunovant.com/investors/news-events/press-releases/detail/25/immunovant-to-present-at-the-stifel-2021-virtual-healthcare https://www.immunovant.com/investors/news-events/press-releases/detail/24/immunovant-reports-financial-results-for-the-quarter-ended https://www.immunovant.com/investors/news-events/press-releases/detail/23/immunovant-to-participate-in-roivant-rd-day-2021 https://www.immunovant.com/investors/news-events/press-releases/detail/22/immunovant-appoints-renee-barnett-as-chief-financial-officer https://www.immunovant.com/investors/news-events/press-releases/detail/21/immunovant-reports-financial-results-for-the-quarter-ended https://www.immunovant.com/investors/news-events/press-releases/detail/20/immunovant-to-report-financial-results-for-quarter-ended https://www.immunovant.com/investors/news-events/press-releases/detail/1/immunovant-receives-200-million-strategic-investment-from https://www.immunovant.com/investors/news-events/press-releases/detail/2/immunovant-provides-corporate-updates-and-reports-financial https://www.immunovant.com/investors/news-events/press-releases/detail/3/immunovant-reports-financial-results-for-the-quarter-and https://www.immunovant.com/investors/news-events/press-releases/detail/4/immunovant-announces-voluntary-pause-in-clinical-dosing-of https://www.immunovant.com/investors/news-events/press-releases/detail/5/immunovant-appoints-rita-jain-chief-medical-officer-and https://www.immunovant.com/investors/news-events/press-releases/detail/6/immunovant-reports-financial-results-for-the-quarter-and https://www.immunovant.com/investors/news-events/press-releases/detail/7/immunovant-announces-closing-of-200-0-million-public https://www.immunovant.com/investors/news-events/press-releases/detail/8/immunovant-announces-pricing-of-public-offering https://www.immunovant.com/investors/news-events/press-releases/detail/9/immunovant-announces-positive-topline-results-from https://www.immunovant.com/investors/news-events/press-releases/detail/10/immunovant-appoints-michael-elliott-chief-scientific-officer https://www.immunovant.com/investors/news-events/press-releases/detail/11/immunovant-reports-financial-results-for-the-quarter-ended https://www.immunovant.com/investors/news-events/press-releases/detail/12/immunovant-reports-financial-results-for-the-quarter-and https://www.immunovant.com/investors/news-events/press-releases/detail/13/immunovant-announces-redemption-of-warrants-and-achievement https://www.immunovant.com/investors/news-events/press-releases/detail/14/immunovant-announces-closing-of-139-4-million-public https://www.immunovant.com/investors/news-events/press-releases/detail/15/immunovant-announces-pricing-of-121-2-million-public https://www.immunovant.com/investors/news-events/press-releases/detail/16/immunovant-announces-positive-clinical-results-from-ongoing https://www.immunovant.com/investors/news-events/press-releases/detail/17/immunovant-reports-financial-results-for-the-quarter-and https://www.immunovant.com/investors/news-events/press-releases/detail/18/immunovant-to-present-at-the-9th-annual-svb-leerink-global https://www.immunovant.com/investors/news-events/press-releases/detail/19/immunovant-sciences-ltd-closes-transaction-with-health https://www.immunovant.com/privacy-policy https://www.immunovant.com/terms-of-use https://www.immunovant.com/disclaimer https://www.immunovant.com/sitemap